{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:25:36Z","timestamp":1790007936067,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd000207","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000}}],"reference-count":160,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000207.pub2","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T12:16:08Z","timestamp":1521461768000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cholinergic medication for antipsychotic-induced tardive dyskinesia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Irina","family":"Tammenmaa-Aho","sequence":"first","affiliation":[{"name":"Helsinki City Hospital; Palliative Care (Home Hospital Services); Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Asher","sequence":"additional","affiliation":[{"name":"Home; 14 Arlozorov St. Kfar Saba Israel 4445317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Soares-Weiser","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Editorial Unit; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"key":"10.1002\/14651858.CD000207.pub2-BIB0001|cit1","volume-title":"Lecithin therapy for tardive dyskinesia [dissertation]","author":"Beckham","year":"1981"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4088\/JCP.v68n0309","article-title":"Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial","volume":"68","author":"Caroff","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0003|cit3","unstructured":"NCT00164242 Treatment of tardive dyskinesia with galantamine www.ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00492207","article-title":"Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study","volume":"65","author":"Montigny","year":"1979","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0005|cit5","first-page":"149","article-title":"A crossover study of lecithin treatment of tardive dyskinesia","volume":"51","author":"Gelenberg","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/00048678109159413","article-title":"Double blind controlled trial of deanol in tardive dyskinesia","volume":"15","author":"George","year":"1981","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000207.pub2-BIB0007|cit7","first-page":"725","article-title":"Cholinergic enhancement in tardive dyskinesia","volume":"24","author":"Jackson","year":"1978","journal-title":"Current Therapeutic Research"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0008|cit8","first-page":"85","article-title":"Lecithin administration in tardive dyskinesia: clinical and biomedical correlates","volume":"16","author":"Jackson","year":"1981","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD000207.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1176\/ajp.136.11.1458","article-title":"Treatment of tardive dyskinesia with lecithin","volume":"136","author":"Jackson","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0010|cit10","first-page":"29","article-title":"The effectiveness of rivastigmine in reducing tardive dyskinesia symptoms in patients with schizophrenia","volume":"20","author":"Jahanian","year":"2014","journal-title":"Iranian Journal of Psychiatry and Clinical Psychology"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0011|cit11","first-page":"103","article-title":"Therapy with dimethylaminoethanol (Deanol) in late dyskinesias induced by neuroleptics","volume":"126","author":"Kocher","year":"1980","journal-title":"Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00369796","article-title":"Deanol in tardive dyskinesia: a double-blind study (author's transl)","volume":"222","author":"Bockenheimer","year":"1976","journal-title":"Archiv fur Psychiatrie und Nervenkrankheiten"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0013|cit13","volume-title":"Uber die therapeutische Wirksamkeit von Dimethylaminoaethanol bei neuroleptikainduzierten Sp\u00e4thyperkinesen [dissertation]","author":"Lucius","year":"1978"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/JCP.0b013e3181934475","article-title":"Effect of donepezil on tardive dyskinesia","volume":"29","author":"Ogunmefun","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0015|cit15","volume-title":"Lecithin treatment for tardive dyskinesia: a clinical evaluation [dissertation]","author":"Price","year":"1982"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archneur.1977.00500240044007","article-title":"Deanol acetamidobenzoate treatment in choreiform movement disorders","volume":"34","author":"Tarsy","year":"1977","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0017|cit17","first-page":"267","article-title":"Experimental design and analysis for determination of improvement rating by video imaging - A double-blind placebo-controlled study for meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia","volume":"19","author":"Ojima","year":"1991","journal-title":"Rinsho Hyoka (Clinical Evaluation)"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0018|cit18","first-page":"455","article-title":"Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia - A double-blind placebo-controlled study","volume":"18","author":"Yagi","year":"1990","journal-title":"Rinsho Hyoka (Clinical Evaluation)"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0019|cit19","unstructured":"Yagi G Kamizima K Miura S Meclofenoxate (lucidril) in tardive dyskinesia - a double-blind placebo-controlled study 303"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0020|cit20","first-page":"87","article-title":"Lecithin treatment of tardive dyskinesia - a progress report","volume":"18","author":"Anderson","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD000207.pub2-BIB0021|cit21","first-page":"1445","article-title":"The safety of lecithin diet supplementation in schizophrenic patients","volume":"17","author":"Yackulic","year":"1982","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0022|cit22","unstructured":"Bartels M Mezger G Schmalzing G Schonle PW Long-term treatment of tardive dyskinesia with lecithin Proceedings of the Symposium der Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie Nuernberg, Germany 1981"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0023|cit23","first-page":"303","article-title":"Lecithin in the treatment of tardive dyskinesia","volume":"3","author":"Branchey","year":"1979","journal-title":"Communications in Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD000207.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4088\/JCP.v62n1004","article-title":"Treatment of tardive dyskinesia with donepezil: A pilot study","volume":"62","author":"Caroff","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4088\/JCP.v62n0210e","article-title":"Treatment of tardive dyskinesia with donepezil [letter]","volume":"62","author":"Caroff","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD000207.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1176\/ajp.132.8.864","article-title":"Deanol in the treatment of tardive dyskinesia","volume":"132","author":"Casey","year":"1975","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00426532","article-title":"Pharmacological characterization of tardive dyskinesia","volume":"54","author":"Casey","year":"1977","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00427135","article-title":"Mood alterations during deanol therapy","volume":"62","author":"Casey","year":"1979","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0029|cit29","first-page":"20","article-title":"Efficacies of agents related to GABA, dopamine and acetylcholine in the treatment of tardive dyskinesia","volume":"14","author":"Chien","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1056\/NEJM197504242921720","article-title":"Deanol for tardive dyskinesia","volume":"292","author":"Crane","year":"1975","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0031|cit31","first-page":"71","article-title":"Treatment of phenothiazine induced bulbar persistent dyskinesia with deanol acetamidobenzoate","volume":"36","author":"Curran","year":"1975","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJM197507172930317","article-title":"Choline for tardive dyskinesia","volume":"293","author":"Davis","year":"1975","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD000207.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0024-3205(76)90095-3","article-title":"Choline in tardive dyskinesia and Huntington's disease","volume":"19","author":"Davis","year":"1976","journal-title":"Life Sciences"},{"issue":"7","key":"10.1002\/14651858.CD000207.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1176\/ajp.134.7.807","article-title":"Deanol in tardive dyskinesia","volume":"134","author":"Davis","year":"1977","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0035|cit35","first-page":"23","article-title":"Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis","volume":"13","author":"Davis","year":"1978","journal-title":"Biological Psychiatry"},{"issue":"5981","key":"10.1002\/14651858.CD000207.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/bmj.3.5981.466","article-title":"Deanol in tardive dyskinesia","volume":"3","author":"Silva","year":"1975","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0006-3223(85)90177-5","article-title":"Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy","volume":"20","author":"Domino","year":"1985","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJM197502062920617","article-title":"Dimethylaminoethanol for tardive dyskinesia","volume":"292","author":"Escobar","year":"1975","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00437417","article-title":"Cholinergic suppression of tardive dyskinesia","volume":"37","author":"Fann","year":"1974","journal-title":"Psychopharmacologia (Berlin)"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00429543","article-title":"Deanol in tardive dyskinesia: a preliminary report","volume":"42","author":"Fann","year":"1975","journal-title":"Psychopharmacologia (Berlin)"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0041|cit41","first-page":"106","article-title":"Chronic deanol administration in tardive dyskinesia","volume":"19","author":"Fann","year":"1976","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD000207.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1176\/ajp.136.6.772","article-title":"Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study","volume":"136","author":"Gelenberg","year":"1979","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-440X(89)90111-9","article-title":"CDP-Choline for the treatment of tardive dyskinesia: A small negative series","volume":"30","author":"Gelenberg","year":"1989","journal-title":"Comprehensive Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1056\/NEJM197504242921720","article-title":"Deanol for tardive dyskinesia","volume":"292","author":"Granacher","year":"1975","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0046|cit45","first-page":"55","article-title":"Effects of choline on tardive dyskinesia and other movement disorders","volume":"14","author":"Growdon","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"issue":"10","key":"10.1002\/14651858.CD000207.pub2-BIB0045|cit46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM197709082971002","article-title":"Oral choline administration to patients with tardive dyskinesia","volume":"297","author":"Growdon","year":"1977","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/21548331.1978.11707296","article-title":"Dietary enhancement of CNS neurotransmitters","volume":"13","author":"Wurtman","year":"1978","journal-title":"Hospital Practice"},{"issue":"1-2","key":"10.1002\/14651858.CD000207.pub2-BIB0048|cit48","first-page":"47","article-title":"Treatment of tardive dyskinesias with 7-metoxytacrine - II","volume":"36","author":"Hanus","year":"1993","journal-title":"Sbornik vedeckych praci Lekarske fakulty Karlovy univerzity v Hradci Kralove. Supplementum."},{"issue":"12","key":"10.1002\/14651858.CD000207.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1176\/ajp.140.12.1629","article-title":"The use of tacrine for tardive dyskinesia","volume":"140","author":"Ingram","year":"1983","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-3223(86)90142-3","article-title":"Meclofenoxate therapy in tardive dyskinesia: A preliminary report","volume":"21","author":"Izumi","year":"1986","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0051|cit51","first-page":"197","article-title":"Effect of lecithin on tardive dyskinesia","volume":"22","author":"Joe","year":"1985","journal-title":"Korea University Medical Journal"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000117629","article-title":"Deanol, lithium and placebo in the treatment of tardive dyskinesia: A double-blind crossover study","volume":"4","author":"Jus","year":"1978","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/jnnp.37.8.941","article-title":"Effect of cholinergic and anticholinergic agents on tardive dyskinesia","volume":"27","author":"Klawans","year":"1974","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD000207.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1176\/ajp.133.8.978","article-title":"Treatment of tardive dyskinesia with deanol","volume":"133","author":"Kumar","year":"1976","journal-title":"American Journal of Psychiatry"},{"issue":"7919","key":"10.1002\/14651858.CD000207.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(75)92592-1","article-title":"Deanol in spontaneous and induced dyskinesias","volume":"1","author":"Laterre","year":"1975","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00004714-198808000-00004","article-title":"Pharmacologic characterization of tardive dyskinesia","volume":"8","author":"Lieberman","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2466\/pr0.1979.45.2.415","article-title":"Electromyographic assessment of dimethylaminoethanol (deanol) in treatment of tardive dyskinesia","volume":"45","author":"Lonowski","year":"1979","journal-title":"Psychological Reports"},{"issue":"3, Special issu","key":"10.1002\/14651858.CD000207.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0924-977X(94)90192-9","article-title":"An open trial with 7-methoxytacrine in tardive dyskinesia","volume":"4","author":"Marsalek","year":"1994","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0059|cit59","first-page":"7","article-title":"7-MEOTA in the treatment of tardive dyskinesia. Double-blind placebo controlled study","volume":"38","author":"Marsalek","year":"1997","journal-title":"Homeostasis -PRAHA- 39th, Psychopharmacological meeting, Jesenik, Spa; Czech Republi"},{"issue":"12","key":"10.1002\/14651858.CD000207.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1176\/ajp.133.12.1467a","article-title":"Failure of deanol in treating tardive dyskinesia","volume":"133","author":"Mehta","year":"1976","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD000207.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1176\/ajp.137.10.1202","article-title":"Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes","volume":"137","author":"Moore","year":"1980","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S0033291700015312","article-title":"Variable clinical response to choline in tardive dyskinesia","volume":"14","author":"Nasrallah","year":"1984","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0063|cit63","first-page":"56","article-title":"Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management","volume":"47","author":"Nasrallah","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF00431469","article-title":"Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism","volume":"84","author":"Noring","year":"1984","journal-title":"Psychopharmacology"},{"issue":"19","key":"10.1002\/14651858.CD000207.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.1978.03280460065020","article-title":"Double-blind evaluation of deanol in tardive dyskinesia","volume":"239","author":"Penovich","year":"1978","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD000207.pub2-BIB0066|cit66","first-page":"531","article-title":"Double-blind study of lecithin in the treatment of persistent tardive dyskinesia","volume":"73","author":"Perez-Cruet","year":"1981","journal-title":"Boletin Asociacion Medica Puerto Rico"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0067|cit67","first-page":"628","article-title":"Oral choline in tardive dyskinesia","volume":"76","author":"Ray","year":"1982","journal-title":"Indian Journal of Medical Research"},{"issue":"5","key":"10.1002\/14651858.CD000207.pub2-BIB0068|cit68","first-page":"289","article-title":"Cholinergic system in the pathophysiology of tardive dyskinesias","volume":"84","author":"Rektor","year":"1988","journal-title":"Ceskoslovenska Psychiatrie"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF00426709","article-title":"Deanol in the treatment of tardive dyskinesia","volume":"52","author":"Simpson","year":"1977","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD000207.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1176\/ajp.134.7.769","article-title":"Cholinergic influences in tardive dyskinesia","volume":"134","author":"Tamminga","year":"1977","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0165-1781(86)90002-8","article-title":"Lithium and lecithin in tardive dyskinesia: an update","volume":"19","author":"Volavka","year":"1986","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0072|cit72","first-page":"305","article-title":"First experience with the application of 7-methoxytacrine to psychiatric patients","volume":"31","author":"Zapletalek","year":"1989","journal-title":"Activitas Nervosa Superior"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Alabed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000408492","article-title":"Cholinergic treatments for tardive dyskinesia","volume":"21","author":"Alphs","year":"1983","journal-title":"Modern Problems in Pharmacopsychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD000207.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD000207.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0301-0082(99)00064-7","article-title":"Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?","volume":"61","author":"Andreassen","year":"2000","journal-title":"Progress in Neurobiology"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002130100767","article-title":"Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration","volume":"157","author":"Andreassen","year":"2001","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0078|cit78","volume-title":"Tardive dyskinesia: a task force report of the American Psychiatric Association","author":"American Psychiatric Association","year":"1992"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","article-title":"Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study","volume":"69","author":"Ascher-Svanum","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-200004000-00011","article-title":"Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies","volume":"20","author":"Ballesteros","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0082|cit82","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects","volume-title":"Antipsychotic Drugs and their Side-effects","author":"Barnes","year":"1993"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.154.4.523","article-title":"The course of tardive dyskinesia in patients on long-term neuroleptics","volume":"154","author":"Bergen","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"43","key":"10.1002\/14651858.CD000207.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21430","article-title":"Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia","volume":"21","author":"Bergman","year":"2017 Aug","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub2","article-title":"Donepezil for dementia due to Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD000207.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.pub4","article-title":"Rivastigmine for Alzheimer's disease","author":"Birks","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0090|cit90","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radical in neuroleptic-induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0092|cit92","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1995"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0920-9964(98)00160-1","article-title":"Tardive dyskinesia and atypical antipsychotic drugs","volume":"35","author":"Casey","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/npp.1993.26","article-title":"Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence","volume":"8","author":"Cavallaro","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCP.0b013e3181929f94","article-title":"Mortality rates among patients with schizophrenia and tardive dyskinesia","volume":"29","author":"Chong","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0097|cit97","unstructured":"Clarke M Oxman AD Cochrane Reviewers\u00b4 Handbook 4.1.4 [updated October 2001] Cochrane Database of Systematic Reviews 2001 Clarke M, Oxman AD, editors. Cochrane Reviewers Handbook 4.1.4 [updated October 2001]. In: The Cochrane Library, Issue 4, 2001. Oxford: Update Software. Updated quarterly."},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematicreview of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0100|cit100","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD000207.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD000207.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Essali","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0108|cit108","article-title":"The crossover study","volume-title":"The Design and Analysis of Clinical Experiments","author":"Fleiss","year":"1984"},{"issue":"7","key":"10.1002\/14651858.CD000207.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0447.1988.tb05138.x","article-title":"Tardive dyskinesia","volume":"77","author":"Gerlach","year":"1988","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","article-title":"Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication","volume":"157","author":"Glazer","year":"1990","journal-title":"British Journal of Psychiatry"},{"issue":"suppl 4","key":"10.1002\/14651858.CD000207.pub2-BIB0112|cit112","first-page":"15","article-title":"Review of incidence studies of tardive dyskinesia associated with typical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/1098-2396(20010101)39:1<51::AID-SYN7>3.0.CO;2-Z","article-title":"Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats","volume":"39","author":"Grimm","year":"2001","journal-title":"Synapse"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0115|cit115","first-page":"534","article-title":"Abnormal Involuntary Movement Scale (AIMS)","volume-title":"ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76-338","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0116|cit116","first-page":"217","article-title":"Clinical Global Impressions (CGI)","volume-title":"ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76-338","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0118|cit118","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD000207.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"suppl 4","key":"10.1002\/14651858.CD000207.pub2-BIB0120|cit120","first-page":"27","article-title":"Tardive dyskinesia in older patients","volume":"61","author":"Jeste","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0122|cit122","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"11","key":"10.1002\/14651858.CD000207.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000207.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD000207.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second-generation antipsychotics for schizophrenia: can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0127|cit127","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009444","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","author":"Li","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Supplement 29","key":"10.1002\/14651858.CD000207.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747.pub3","article-title":"Galantamine for Alzheimer's disease and mild cognitive impairment","author":"Loy","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5 Suppl B","key":"10.1002\/14651858.CD000207.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004747.pub2","article-title":"Cholinesterase inhibitors for Parkinson's disease dementia","author":"Maidment","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomized controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0133|cit133","first-page":"44","article-title":"Prevalence of tardive dyskinesia and all-cause mortality amongst patients in a large psychiatirc institute in Rio de Janeiro","volume":"38","author":"Martins","year":"2011","journal-title":"Revista de Psiquiatria Cl\u00ednica"},{"issue":"12","key":"10.1002\/14651858.CD000207.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v68n1210","article-title":"Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis","volume":"68","author":"Miller","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Brtish Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0137|cit137","unstructured":"NICE Psychosis and schizophrenia in adults: treatment and management NICE clinical guideline 178 (guidance.nice.org.uk\/cg178) 2014"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0139|cit139","article-title":"Crossover trials","volume-title":"Clinical trials. A Practical Approach","author":"Pocock","year":"1983"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006504.pub2","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","author":"Rolinski","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1192\/bjp.bp.106.035063","article-title":"Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics","volume":"191","author":"Rosenheck","year":"2007","journal-title":"British Journal of Psychiatry : the journal of mental science"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0142|cit142","first-page":"431","article-title":"Clinical research for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00496058","article-title":"A rating scale for tardive dyskinesia","volume":"64","author":"Simpson","year":"1979","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Changes in prevalence, severity and recovery in tardive dyskinesia with age","volume":"37","author":"Smith","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0147|cit147","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0148|cit148","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD000207.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.pnpbp.2004.05.045","article-title":"Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials","volume":"28","author":"Tammenmaa","year":"2004 Nov","journal-title":"Progress in Neuropsychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handbook of Clinical Neurology"},{"key":"10.1002\/14651858.CD000207.pub2-BIB0153|cit153","doi-asserted-by":"crossref","DOI":"10.3109\/9780203092835","volume-title":"The Maudsley Prescribing Guidelines (10th Edition)","author":"Taylor","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD000207.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"4","key":"10.1002\/14651858.CD000207.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/21548331.1978.11707296","article-title":"Dietary enhancement of CNS neurotransmitters","volume":"13","author":"Wurtman","year":"1978 Mar","journal-title":"Hospital Practice"},{"issue":"7","key":"10.1002\/14651858.CD000207.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD000207.pub2-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000207.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(99)00021-3","article-title":"The treatment of tardive dyskinesia - a systematic review and meta-analysis","volume":"39","author":"Soares-Weiser","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD000207.pub2-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000207.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T07:48:51Z","timestamp":1668757731000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000207.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,19]]},"references-count":160,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000207.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,19]]}}}